Overview

Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.

Status:
Completed

Trial end date:
2009-01-01

Target enrollment:
0

Participant gender:
All

Summary

To evaluate the efficacy and safety of fesoterodine in comparison to placebo for overactive bladder.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Pfizer

Treatments:

Fesoterodine

Criteria

Inclusion Criteria:

- Adult OAB patients who present with OAB symptoms, including micturitions >= 8 per day
and urgency urinary incontinence >= 1 per day.

Exclusion Criteria:

- Patient has known hypersensitivity to the active substance (fesoterodine fumarate) or
to peanut or soya or any of the excipients.

- Patient has a known neurological disease influencing bladder function.

- Patient has a complication of lower urinary tract pathology potentially responsible
for urgency or incontinence, clinically relevant bladder outlet obstruction or pelvic
organ prolapse.